Aspirin is First-Line Treatment for Migraine and Episodic Tension-Type Headache Regardless of Headache Intensity

被引:10
作者
Lampl, Christian [1 ]
Voelker, Michael [2 ]
Steiner, Timothy J. [3 ]
机构
[1] Konventhospital Barmherzige Brueder, Dept Neurol, Pain & Headache Ctr, A-4020 Linz, Austria
[2] Bayer HealthCare, Leverkusen, Germany
[3] Norwegian Univ Sci & Technol, Dept Neurosci, N-7034 Trondheim, Norway
来源
HEADACHE | 2012年 / 52卷 / 01期
关键词
aspirin; migraine; tension-type headache; stratified care; stepped care; EFFERVESCENT ACETYLSALICYLIC-ACID; EARLY INTERVENTION; SUMATRIPTAN TABLETS; DOUBLE-BLIND; DISABILITY ASSESSMENT; COST-EFFECTIVENESS; CARE STRATEGIES; PAIN; EFFICACY; ALMOTRIPTAN;
D O I
10.1111/j.1526-4610.2011.01974.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objectives. (1) To establish whether pre-treatment headache intensity in migraine or episodic tension-type headache (ETTH) predicts success or failure of treatment with aspirin; and (2) to reflect, accordingly, on the place of aspirin in the management of these disorders. Background.-Stepped care in migraine management uses symptomatic treatments as first-line, reserving triptans for those in whom this proves ineffective. Stratified care chooses between symptomatic therapy and triptans as first-line on an individual basis according to perceived illness severity. We questioned the 2 assumptions underpinning stratified care in migraine that greater illness severity: (1) reflects greater need; and (2) is a risk factor for failure of symptomatic treatment but not of triptans. Methods.-With regard to the first assumption, we developed a rhetorical argument that need for treatment is underpinned by expectation of benefit, not by illness severity. To address the second, we reviewed individual patient data from 6 clinical trials of aspirin 1000 mg in migraine (N = 2079; 1165 moderate headache, 914 severe) and one of aspirin 500 and 1000 mg in ETTH (N = 325; 180 moderate, 145 severe), relating outcome to pre-treatment headache intensity. Results.-In migraine, for headache relief at 2 hours, a small (4.7%) and non-significant risk difference (RD) in therapeutic gain favored moderate pain; for pain freedom at 2 hours, therapeutic gains were almost identical (RD: -0.2%). In ETTH, for headache relief at 2 hours, RDs for both aspirin 500 mg (-4.2%) and aspirin 1000 mg (-9.7%) favored severe pain, although neither significantly; for pain freedom at 2 hours, RDs (-14.2 and -3.6) again favored severe pain. Conclusion.-In neither migraine nor ETTH does pre-treatment headache intensity predict success or failure of aspirin. This is not an arguable basis for stratified care in migraine. In both disorders, aspirin is first-line treatment regardless of headache intensity.
引用
收藏
页码:48 / 56
页数:9
相关论文
共 52 条
  • [11] Efficacy and tolerability of sumatriptan tablets in a fast-disintegrating, rapid-release formulation for the acute treatment of migraine: Results of a multicenter, randomized, placebo-controlled study
    Carpay, J
    Schoenen, J
    Ahmad, F
    Kinrade, F
    Boswell, D
    [J]. CLINICAL THERAPEUTICS, 2004, 26 (02) : 214 - 223
  • [12] Diener Hans-Christoph, 2006, Expert Rev Neurother, V6, P563, DOI 10.1586/14737175.6.4.563
  • [13] Placebo-controlled comparison of effervescent acetylsalicylic acid, sumatriptan and ibuprofen in the treatment of migraine attacks
    Diener, HC
    Bussone, G
    de Liano, H
    Eikermann, A
    Englert, R
    Floeter, T
    Gallai, V
    Göbel, H
    Hartung, E
    Jimenez, MD
    Lange, R
    Manzoni, GC
    Mueller-Schwefe, G
    Nappi, G
    Pinessi, L
    Prat, J
    Puca, FM
    Titus, F
    Voelker, M
    [J]. CEPHALALGIA, 2004, 24 (11) : 947 - 954
  • [14] Efficacy of 1,000 mg effervescent acetylsalicylic acid and sumatriptan in treating associated migraine symptoms
    Diener, HC
    Eikermann, A
    Gessner, U
    Göbel, H
    Haag, G
    Lange, R
    May, A
    Muller-Schwefer, G
    Voelker, M
    [J]. EUROPEAN NEUROLOGY, 2004, 52 (01) : 50 - 56
  • [15] Almotriptan improves response rates when treatment is within 1 hour of migraine onset
    Dowson, AJ
    Massiou, H
    Lainez, JM
    Cabarrocas, X
    [J]. HEADACHE, 2004, 44 (04): : 318 - 322
  • [16] EFNS guideline on the drug treatment of migraine - revised report of an EFNS task force
    Evers, S.
    Afra, J.
    Frese, A.
    Goadsby, P. J.
    Linde, M.
    May, A.
    Sandor, P. S.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2009, 16 (09) : 968 - 981
  • [17] Triptans (serotonin, 5-HT1B/1D agonists) in migraine:: detailed results and methods of a meta-analysis of 53 trials
    Ferrari, MD
    Goadsby, PJ
    Roon, KI
    Lipton, RB
    [J]. CEPHALALGIA, 2002, 22 (08) : 633 - 658
  • [18] Should we advise patients to treat migraine attacks early?
    Ferrari, MD
    [J]. CEPHALALGIA, 2004, 24 (11) : 915 - 917
  • [19] Treating early versus treating mild: Timing of migraine prescription medications among patients with diagnosed migraine
    Foley, KA
    Cady, R
    Martin, V
    Adelman, J
    Diamond, M
    Bell, CF
    Dayno, JM
    Hu, XH
    [J]. HEADACHE, 2005, 45 (05): : 538 - 545
  • [20] Self-medication of migraine and tension-type headache: summary of the evidence-based recommendations of the Deutsche Migrane und Kopfschmerzgesellschaft (DMKG), the Deutsche Gesellschaft fur Neurologie (DGN), the A-sterreichische Kopfschmerzgesellschaft (A-KSG) and the Schweizerische Kopfwehgesellschaft (SKG)
    Haag, Gunther
    Diener, Hans-Christoph
    May, Arne
    Meyer, Christian
    Morck, Hartmut
    Straube, Andreas
    Wessely, Peter
    Evers, Stefan
    [J]. JOURNAL OF HEADACHE AND PAIN, 2011, 12 (02) : 201 - 217